Eric Ng
News Editor, Climate
Eric joined the Post in 1998 after brief stints in a trading company, and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has over 20 years of experience covering China's energy, mining and industrial materials sectors, and has reported on China's healthcare and biotechnology sectors for three years. Currently, he leads the Post's coverage on climate change, energy transition and sustainability topics. Eric has a Masters of Business Administration degree.
Eric joined the Post in 1998 after brief stints in a trading company, and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has over 20 years of experience covering China's energy, mining and industrial materials sectors, and has reported on China's healthcare and biotechnology sectors for three years. Currently, he leads the Post's coverage on climate change, energy transition and sustainability topics. Eric has a Masters of Business Administration degree.
Areas of Expertise:
Energy, industrial materials, biotechnology Languages Spoken:
English, Mandarin, Cantonese
China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.
Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.
The start-up aims to launch a pair of satellites within the next 18 months, followed by another five to create a constellation.
Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.
Advertisement
Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.
Chinese firms are seeking new markets amid US tariff changes and potential reviews by the UK and EU, DHL Express CEO says.
Global trade volume set to grow 2.5 per cent annually through 2029, roughly matching the rate in the past 10 years, research says.
Aiming to grow sales to US$300 million in 2027, the company is eyeing a Nasdaq IPO and then a Hong Kong secondary listing.
The non-invasive blood test helps in the early detection of the fifth leading cause of cancer deaths globally.
The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.
Sungrow’s filing comes amid the Trump administration’s roll-out of new import tariffs covering China-made solar energy products.
Firm enters joint venture to cut diesel emissions by building onshore power hookups for ships in ports.
Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.
The US company is working with a unit of China’s Didi Global in a pilot project for such tyres, which can enhance safety and efficiency.
September yields at least 23 listing applications from mainland biotech firms eyeing the city’s lucrative fundraising market.
The Grand Tourer, designed for high-speed, long-distance journeys and priced above US$100,000, will be produced in Tai Po, sources say.
World’s first vehicle carrier powered by methanol and conventional fuel, the CM Hong Kong, calls on the city on its maiden voyage.
CM Hong Kong docks in Tsing Yi on maiden voyage, as city boosts its role in sustainable maritime fuel bunkering.
The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.
Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.
China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.
Chief executive says a ‘clear and stable local market’ is a key prerequisite for green aviation fuel hub ambitions.
Outlook brightens for beleaguered supply chain, with makers of polysilicon possibly returning to profitability this month.
GCL and Yunfeng leverage Hong Kong’s booming stock market to secure funding for expansion, tech upgrades, and virtual asset ventures.
Average annual gold output grew 21.4 per cent between 2022 and 2024, making it the world’s 11th biggest producer last year, said the unit of Zijin Mining Group.
Beijing’s push to use artificial intelligence to find new drugs is paying off, with China-based companies earning billions by licensing discoveries to Western firms.
Demand for anti-obesity drugs has expanded along with people’s waistlines, and Chinese companies are seeking to cash in with new treatments.
Novel drug roll-outs and revenue from licensing buoy results.
The company plans to ship components made at its plant in Shenzhen to Hong Kong where robots for overseas clients would be assembled.
